Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.

doi:10.1016/j.ygyno.2020.07.025

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.

Gynecologic oncology - 1 Oct 2020

Oaknin Ana, Friedman Claire F, Roman Lynda D, D'Souza Anishka, Brana Irene, Bidard François-Clement, Goldman Jonathan, Alvarez Edwin A, Boni Valentina, ElNaggar Adam C, Passalacqua Rodolfo, Do Khanh T M, Santin Alessandro D, Keyvanjah Kiana, Xu Feng, Eli Lisa D, Lalani Alshad S, Bryce Richard P, Hyman David M, Meric-Bernstam Funda, Solit David B, Monk Bradley J

Abstract excerpt

OBJECTIVE: Somatic HER2 mutations occur in ~5% of cervical cancers and are considered oncogenic and associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is active in multiple HER2-mutant cancers. SUMMIT is a phase II basket trial investigating the efficacy and safety of neratinib in solid tumors. METHODS: Patients with HER2-mutant, persistent, metastatic/recurrent cervical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to Nausea

Share to Neoplasm Recurrence, Local

Share to Progression-Free Survival

Share to Quinolines

Share to Receptor, ErbB-2

Share to Uterine Cervical Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32723675
DOI: 10.1016/j.ygyno.2020.07.025
PMCID: PMC8336424

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.PMID 32723675Read ↗

Targeting HER2 mutant advanced biliary tract cancers with neratinib: results from the SUMMIT ‘basket’ trialSemantic proximity Read ↗

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.Semantic proximity Read ↗

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.Semantic proximity Read ↗

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.Semantic proximity Read ↗

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.Semantic proximity Read ↗

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitorsSemantic proximity Read ↗

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.Semantic proximity Read ↗

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancerSemantic proximity Read ↗

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.Semantic proximity Read ↗

Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.Semantic proximity Read ↗

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapySemantic proximity Read ↗

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.